Ballentine Partners, LLC Geron Corp Transaction History
Ballentine Partners, LLC
- $6.57 Billion
- Q2 2025
A detailed history of Ballentine Partners, LLC transactions in Geron Corp stock. As of the latest transaction made, Ballentine Partners, LLC holds 82,084 shares of GERN stock, worth $110,813. This represents 0.0% of its overall portfolio holdings.
Number of Shares
82,084Holding current value
$110,813% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GERN
# of Institutions
296Shares Held
509MCall Options Held
790KPut Options Held
463K-
Ra Capital Management, L.P. Boston, MA60.4MShares$81.5 Million1.99% of portfolio
-
Black Rock Inc. New York, NY46.6MShares$62.8 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT38.2MShares$51.5 Million2.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA35.6MShares$48.1 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA27.2MShares$36.8 Million11.75% of portfolio
About GERON CORP
- Ticker GERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 377,819,008
- Market Cap $510M
- Description
- Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...